- The Debiopharm Group and Curis, Inc (NASDAQ:CRIS) announced this morning the beginning of a Phase I/II clinical study of Debiopharm’s development-stage Debio 0932, a second-generation … Continue Reading
Read nowResearch - Short interest in ResMed Inc. (NYSE:RMD) is at its highest point this year, signaling that investors are growing increasingly bearish on the company’s valuation and … Continue Reading
Read nowLong Ideas - Speculation on the future of Alzheimer’s treatments has been at the forefront of major pharma and biotech news this month. Pfizer (NYSE:PFE) and Elan’s (NYSE:ELN) … Continue Reading
Read now- In a post-market announcement last night, Novavax (NASDAQ:NVAX) said they have delayed trials of their influenza vaccine until 2013 after the FDA denied fast-track status … Continue Reading
Read nowLong Ideas - Among the next significant events in pharma and biotech is the FDA decision on Kyprolis (carfilzomib), Onyx Pharmaceuticals’ (NASDAQ:ONXX)next-generation treatment for multiple myeloma. On July … Continue Reading
Read now